The heart in thalassaemia

European Heart Journal

Volumn 23, Issue 2, 2002, Pages 102-105

  Walker, J M ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON;

CARDIOTOXICITY; CARDIOVASCULAR EFFECT; EDITORIAL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IRON OVERLOAD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THALASSEMIA;

HEART DISEASES; HUMANS; THALASSEMIA;

EID: 0036401485     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2850     Document Type: Editorial

References (65)

1. Hill AV. Molecular epidemiology of the thalassaemias (including haemoglobin E). London: Bailliere Tindall. 1992: Baillieres Clinical Haematology 5: 209-38.
2. Weatherall DJ. Anaemia as a World Health Problem. Oxford: Oxford University Press, Oxford Textbook of Medicine, 2001: 3463-82.
3. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J 1962; ii: 1577-80.
4. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2.
5. Tenenbein M, Kopelow ML, deSa DJ. Myocardial failure and shock in iron poisoning. Hum Toxicol 1988; 7: 281-4.
6. Sanyal SK, Johnson W, Jayalakshmamma B, Green AA. Fatal 'iron heart' in an adolescent: Biochemical and ultrastructural aspects of the heart. Pediatrics 1975; 55: 336-41.
7. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anaemia with hemochromatosis. Circulation 1964; 30: 689.
8. Bannerman RM, Keusch G, Kreimer-Birnbaum M, Vance VK, Vaughan S. Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria. Am J Med 1967; 42: 476-86.
9. Zurlo MG, De Stefano P, Borna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 1989; ii: 27-30.
10. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209-21.
11. Fitchett DH, Coltart DJ, Littler WA et al. Cardiac involvement in secondary haemochromatosis: A catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14: 719-24.
12. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: Histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10: 1239-43.
13. Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986; 8: 436-40.
14. Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP. Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin Lab Haematol 1989; 11: 299-307.
15. Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 1993; 103: 1276-8.
16. Hershko C, Koniju AM et al. Therapeutic potential of iron chelating drugs. Hematologia 1999; 3: 67-71.
17. Di Gregorgio F, Leonardi C, Sciuto C, Cannella A, Pizzarelli G. Intensive intravenous chelation in thalassaemic patients with iron overload. Minerva Pediatrica 1998; 50: 81-5.
18. Wolfe L, Olivieri N, Sallan D et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600-3.
19. Olivieri NF, Nathan DG, MacMillan JH et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-8.
20. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with longterm monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
21. Adams ET, Schwartz KA. Iron-induced myocardial and hepatic lysosomal abnormalities in the guinea pig. Toxicol Pathol 1993; 21: 321-6.
22. Bartfay WJ, Dawood F, Wen WH et al. Cardiac function and cytotoxic aldehyde production in a murine model of chronic irnn-overload. Cardiovasc Res 1999; 43: 892-900.
23. Bartfay WJ, Bartfay E. Iron-overload cardiomyopathy: Evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2000; 2: 49-59.
24. Carthew P, Dorman BM, Edwards RE, Francis JE, Smith AG. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 1993; 69: 217-22.
25. Liu P, Henkelman M, Joshi J et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Can J Cardiol 1996; 12: 155-64.
26. Schwartz KA, Fisher J, Adams ET. Morphologic investigations of the guinea pig model of iron overload. Toxicol Pathol 1993; 21: 311-20.
27. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996; 95: 26-36.
28. Chapman RW, Hussain MA, Gorman A, DM et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. J Clin Pathol 1982; 35: 487-91.
29. Brittenham GM, Cohen AR, McLaren CE et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42: 81-5.
30. Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Archives Pathol Lab Med 1987; 111: 549-54.
31. Johnston DL, Rice L, Vick GW, III, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989; 87: 40-7.
32. Blankenberg F, Eisenberg S, Scheinman MN, Higgins CB. Use of cine gradient echo (GRE) MR in the imaging of cardiac hemochromatosis. J Comput Assist Tomogr 1994; 18: 136-8.
33. Mavrogeni SI, Maris T, Gouliamos A, Vlahos L, Kremastinos DT. Myocardial iron deposition in beta-thalassemia studied by magnetic resonance imaging. Int J Card Imaging 1998; 14: 117-22.
34. Mavrogeni SI, Gotsis ED, Markussis V et al. T2 relaxation time study of iron overload in β-thalassemia. MAGMA 1998; 6: 7-12.
35. Ooi GC, Chen FE, Chan KN et al. Qualitative and quantitative magnetic resonance imaging in haemoglobin H disease: Screening for iron overload. Clin Radiol 1999; 54: 98-102.
36. Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C. Non-invasive myocardial iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol 2000; 41: 348-51.
37. Ernst O, Calvo M, Sergent G, Mizrahi D, Carpentier F. Breath-hold MR cholangiopancreatography using a HASTE sequence: Comparison of single-slice and multislice acquisition techniques. Am J Roentgenol 1997; 169: 1304-6.
38. Anderson L, Holden S, Davis B et al. Early diagnosis of myocardial iron overload in thalassaemia major using T2* cardiovascular magnetic resonance. J Am Coll Cardiol 2001.
39. Aldouri MA, Wonke B, Hoffbrand AV et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation. Acta Haematol 1990; 84: 113-7.
40. Leon MB, Borer JS, Bacharach SL et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med 1979; 301: 1143-8.
41. Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am J Med 1978; 64: 547-55.
42. Nienhuis AW, Griffith P, Strawczynski H et al. Evaluation of cardiac function in patients with thalassemia major. Ann NY Acad Sci 1980; 344: 384-96.
43. Yee H, Mra R, Nyunt KM. Cardiac abnormalities in the thalassaemia syndromes. Southeast Asian J Trop Med Public Health 1984; 15: 414-21.
44. Olson LJ, Baldus WP, Tajik AJ. Echocardiographic features of idiopathic hemochromatosis. Am J Cardiol 1987; 60: 885-9.
45. Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: Polygraphic and echocardiographic evaluation. Eur Heart J 1991; 12: 224-30.
46. Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990; 82: 88-94.
47. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993; 88: 1127-35.
48. Mariotti E, Agostini A, Angelucci E, Cesaroni P, Lucarelli G, Sgarbi E. Cardiac study by dobutamine stress echocardiography in thalassemic patients. Bone Marrow Transplant 1993; 12 (Suppl 1): 14-5.
49. Suarez WA, Snyder SA, Berman BB, Brittenham GM, Patel CR. Preclinical cardiac dysfunction in transfusion-dependent children and young adults detected with low-dose dobutamine stress echocardiography. J Am Soc Echocardiogr 1998; 11: 948-56.
50. Intragumtornchai T, Minaphinant K, Wanichsawat C et al. Echocardiographic features in patients with beta thalassemia/hemoglobin E: A combining effect of anemia and iron load. J Med Assoc Thailand 1994; 77: 57-65.
51. Lattanzi F, Bellotti P, Picano E et al. Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation 1993; 87: 748-54.
52. Kremastinos DT, Toutouzas PK, Vyssoulis GP, Venetis CA, Vretou HP, Avgoustakis DG. Global and segmental left ventricular function in beta-thalassemia. Cardiology 1985; 72: 129-39.
53. Kremastinos DT, Toutouzas PK, Vyssoulis GP, Venetis CA, Avgoustakis DG. Iron overload and left ventricular performance in beta thalassemia. Acta Cardiol 1984; 39: 29-40.
54. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation 1995; 91: 66-71.
55. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61.
56. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos N. Right ventricular cardiomyopathy in β-thalassaemia major. Eur Heart J 2002; 23: 147-56, doi:10.1053/euhj.2001.2709.
57. Grisaru D, Rachmilewitz FA, Mosseri M et al. Cardiopulmonary assessment in β-thalassaemia major. Chest 1990; 98: 1138-42.
58. Koren A, Garty I, Antonelli D, Katzuni E. Right ventricular cardiac dysfunction in beta-thalassemia major. Am J Dis Child 1987; 141: 93-6.
59. Piatti G, Allegra L, Ambrosetti U, Cappellini MD, Turati F, Fiorelli G. Beta-thalassemia and pulmonary function. Haematologica 1999; 84: 804-8.
60. Tai DY, Wang YT, Lou J, Wang WY, Mak KH, Cheng HK. Lungs in thalassaemia major patients receiving regular transfusion. Eur Respir J 1996; 9: 1389-94.
61. Lesnefsky EJ, Allen KG, Carrea FP, Horwitz LD. Ironcatalyzed reactions cause lipid peroxidation in the intact heart. J Mol Cell Cardiol 1992; 24: 1031-8.
62. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998; 850: 191-201.
63. Lesnefsky EJ. Tissue iron overload and mechanisms of ironcatalyzed oxidative injury. Adv Exp Med Biol 1994; 366: 129-46.
64. Weatherall DJ. Single gene disorders or complex traits: Lessons from the thalassaemias and other monogenic diseases. BMJ 2000; 321: 1117-20.
65. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nature Rev Gen 2001; 2: 245-55.